* To boost annual R&D spending to about $300 mln (Adds managing director comments)
MUMBAI, March 25 (Reuters) - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said on Wednesday its $3.2 billion acquisition of smaller rival Ranbaxy Laboratories Ltd will not restrict it from making further large acquisitions.
MUMBAI, Feb 28 (Reuters) - A U.S. federal judge has denied Indian generic drugmaker Ranbaxy Laboratories Ltd 's bid to reinstate approvals granted to it to launch the first copies of the heartburn...
Sun Pharmaceuticals Industries and Ranbaxy , came through earlier this week ..... positive on the merger, as we believe Ranbaxy 's OTC and specialty drugs portfolio ..... are also present in the acquired Ranbaxy business. We believe the stock is
Quarterly revenue for the yet-to-merge Ranbaxy business was up 16% and profit turned ..... prior period and accounted for 44% of Ranbaxy 's quarterly sales). We believe ..... further enhanced with the addition of Ranbaxy to its portfolio.
largely the result of incorporating Ranbaxy financials into our forecast starting 1 April 2014. We believe the Ranbaxy acquisition will strengthen Sun ..... to expand the operating margins of Ranbaxy post-merger. These include manufacturing
fair value estimate for Sun Pharmaceuticals as we update our model for recent performance and integrate the acquisition of Ranbaxy into our forecast. We also are maintaining our narrow moat rating for the company. Sun continues to post strong growth
April bought Ranbaxy Laboratories for $4 billion from Japan’s Daiichi Sankyo . And French pharmaceutical ..... purchase of Ranbaxy Laboratories , the latter ..... Japan’s Daiichi Sankyo in 2008 bought a 64% stake in Ranbaxy for $4.2
but we remain concerned about possible margin pressure from internal regulatory issues and the upcoming integration of Ranbaxy . Sun's U.S. business continued to lead the charge with 43% growth, as currency benefits and pricing power in many
acquire the ailing Indian pharmaceutical company Ranbaxy in an all-equity transaction. Each Ranbaxy shareholder will receive 0.8 shares of Sun ..... quality control and regulatory problems plaguing Ranbaxy 's recent performance. Assuming Sun can successfully